 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || Biolexa (gentamicin/diethylenetriaminepentaacetic acid) / Hoth Therap
Trial completion, Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Nov 17, 2022
P1, N=31, Completed, Sponsor: Hoth Therapeutics, Inc.
Recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2022 | Trial primary completion date: Jan 2022 --> Sep 2022
- ||||| Biolexa (gentamicin/diethylenetriaminepentaacetic acid) / Hoth Therap
P1/2 data: $HOTH enterprise value $8M extremely undervalued! The lead asset BioLexa technology could be valued billions! Only one indication Atopic dermatitis market opportunities $15-$20B! Currently in phase 1/2 readout 1Q2022 @Amgen $AMGN & @KyowaHakkoUSA should acquire/license Biolexa (Twitter) - Dec 23, 2021
- ||| Biolexa (gentamicin/diethylenetriaminepentaacetic acid) / Hoth Therap
$HOTH developed BioLexa Platform non-corticosteroid approach for atopic dermatitis (Twitter) - Sep 2, 2021
- || Biolexa (gentamicin/diethylenetriaminepentaacetic acid) / Hoth Therap
Enrollment open: Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Jun 7, 2021
P1, N=34, Recruiting, Sponsor: Hoth Therapeutics, Inc.
Recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2022 | Trial primary completion date: Jan 2022 --> Sep 2022 Not yet recruiting --> Recruiting
- || Biolexa (gentamicin/diethylenetriaminepentaacetic acid) / Hoth Therap
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Feb 11, 2021
P1, N=34, Not yet recruiting, Sponsor: Hoth Therapeutics, Inc.
Not yet recruiting --> Recruiting N=64 --> 34 | Trial completion date: Jul 2022 --> Jan 2022 | Initiation date: Oct 2020 --> Mar 2021 | Trial primary completion date: Apr 2022 --> Dec 2021
- ||| Biolexa (gentamicin/diethylenetriaminepentaacetic acid) / Hoth Therap
New P1 trial: Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Sep 9, 2020
P1, N=64, Not yet recruiting, Sponsor: Hoth Therapeutics, Inc.